FOLR2 and neoplasm: Based on these results, we suggest that an FRβ-transported C1 inhibitor such as AGF94 represents an exciting new approach for therapy of HGSOC through its ability to directly target the tumor via uptake by FRα and PCFT, and its effects on the TME, particularly FRβ-expressing TAMs.